GMAB vs. IQV: Genmab vs. IQVIA Stock Comparison

Company Profile

Genmab (GMAB) and IQVIA (IQV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while IQV is classified in Life Sciences Tools & Services.

IQVIA (IQV) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Genmab (GMAB) at 12.07% and IQVIA (IQV) at 21.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Genmab (GMAB) at 16.97% and IQVIA (IQV) at 8.05% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Genmab (GMAB) at 37.15% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Genmab (GMAB) at 19.19% and IQVIA (IQV) at 5.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Genmab (GMAB) at -9.23% and IQVIA (IQV) at 4.67% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and IQVIA (IQV) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but IQV is more stretched: Genmab (GMAB) at 0.82 sits in the higher-leverage quartile and IQVIA (IQV) at 2.40 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Genmab (GMAB) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Genmab (GMAB) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

IQVIA (IQV) at 33.07 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Genmab (GMAB) at 7.68 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while IQVIA (IQV) at 6.73 carries an above-peer premium to book — IQV is pricier on assets.

Valuation Metrics